Is Novavax Still a Good Coronavirus Stock to Buy?
A coronavirus vaccine candidate and billions in government-backed funding to develop it have propelled Novavax (NASDAQ: NVAX) shares around 2,300% higher this year. But with that spectacular run in the rear-view mirror, investors would be right to wonder if there's any more fuel in the tank.
The short answer is yes -- the stock could climb further if the company's SARS-CoV-2 vaccine candidate, NVX-CoV2373, performs well in clinical trials. Before new investors dive in, though, they need to measure the potential upside against a great deal of risk.
Image source: Getty Images.
Source Fool.com
